VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
62 hedge funds and large institutions have $151M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
8% less call options, than puts
Call options by funds: $885K | Put options by funds: $961K
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
Holders
62
Holding in Top 10
1
Calls
$885K
Puts
$961K
Top Buyers
| 1 | +$21.3M | |
| 2 | +$13.9M | |
| 3 | +$5.49M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.43M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$3.4M |
Top Sellers
| 1 | -$4.72M | |
| 2 | -$4.35M | |
| 3 | -$3.88M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$3.77M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.86M |